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ABSTRACT  Natural products and traditional herbal medicine are an 
important source of alternative bioactive compounds but very few 
plant-based preparations have been scientifically evaluated and vali-
dated for their potential as medical treatments. However, a promising 
field in the current therapies based on plant-derived compounds is the 
study of their immunomodulation properties and their capacity to acti-
vate the immune system to fight against multifactorial diseases like 
cancer. In this review we discuss how network pharmacology could help 
to characterize and validate natural single molecules or more complex 
preparations as promising cancer therapies based on their multitarget 
capacities. 
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Over the past decade, immunotherapy has become a 
promising approach to treat cancer and is now being com-
bined with standard chemotherapy and immune response 
activators to improve the outcome for cancer patients [1]. 
However, the rate of drug candidates that are successfully 
translated into clinics advance slowly due to the lack of 
efficacy and the clinical safety or toxicology. Another factor 
that contributes to this phenomenon is the assumption 
that the main aim for new treatments is to find a quite 
selective ligand or immune checkpoint that blocks a single 
target or that stimulates a single pathway [2, 3]. This phi-
losophy of “one gene, one drug, one disease” arises from 
combining genetic reductionism and molecular biology 
technologies that allow us to isolate and characterize “dis-
ease-causing” genes and is justified as the safest approach 
to minimize off-target effects. However, until now no 
“magic bullet” has been described [2].  
Although produced by the plant itself to adapt and in-
teract with the environment, many natural compounds 
have been used as drugs by humans. In the area of cancer 
treatment, it has been shown that around 75% of the med-
ications available are derived or inspired from plants [4]. 
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CRT – calreticulin; DAMP – damage 
associated molecular pattern; DC – dendritic 
cell; DMIM – Distance-based Mutual 
Information Model; ER – endoplasmic 
reticulum; HCV – hepatitis C virus; ICD – 
immunogenic cell death; JTT – juzen-taiho-to; 
NK – natural killer; NP – network 
pharmacology; PDT – photodynamic therapy; 
ROS – reactive oxygen species; SK – shikonin; 
TCM – Traditional Chinese Medicine; UPR – 
unfolded protein response. 
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Today, one of the main advantages of natural products 
relies on their multitarget activity allowing the interaction 
of one compound or a complex fraction with multiple pro-
teins and receptors [5].   
Over time, herbal traditional medicine has been con-
sidered an important alternative to classical western medi-
cine. Although some herbal preparations are very popular 
in our society, very few plant-based preparations have 
been scientifically evaluated and validated for their poten-
tial as medical treatments. In most countries herbal drugs 
are poorly regulated and their safety remains a major con-
cern [6]. However, a promising field in the current thera-
pies based on plant-derived compounds is the study of 
their synergistic activity when administered in combination 
with synthetic anticancer medications [7]. 
In this review, we discuss the importance of the im-
mune system activation by natural compounds in cancer 
treatment in the context of network pharmacology. We 
focus on the multitargeting concept and synergistic activity 
as key tools to treat multifactorial and complex diseases 
such as cancer.   
 
THE IMMUNE SYSTEM AND CANCER 
The interactions between immunity and cancer have been 
the object of numerous studies in pre-clinical models to 
understand how the immune system can repress tumor 
development and exert its protective function. However, in 
recent years, it also became clear that the immune system 
can shape and promote cancer development [8]. 
In 1909 Paul Ehrlich formulated the initial hypothesis 
that host defense may prevent neoplastic cells from devel-
oping into tumors [9]. This idea was refined by the theory 
of immune surveillance against cancer proposed by Burnet 
in 1970 [10], followed by the concept of “3E cancer immu-
noediting” introduced by Dunn and Schreiber in 2002 [11]. 
This last theory postulated that the immune system is able 
to keep in check the development of transformed cells and 
prevent neoplasia during the initial phase of elimination. 
Then, due to genetic instability, cells that are more re-
sistant to the immune attack emerge but remain under the 
constant control of the immune system, during an equilib-
rium phase. The long-term exposure to this “editor” envi-
ronment, favors new populations of tumor variants that 
occasionally will escape the immune system by different 
mechanisms and become clinically detectable and dissemi-
nate [11].  
Since then, important experiments demonstrated that 
endogenous levels of IFN-γ were sufficient to provide pro-
tection against the development of transplanted tumors in 
immunocompetent animals [12]. Further, studies in  
RAG-2-/- mice showed the importance of T lymphocytes in 
tumor immune surveillance [13]. Nowadays, the role of the 
immune system in cancer development has been largely 
acknowledged and clinically exploited for cancer patient’s 
treatment. Even if we are still a long way from understand-
ing all the underlying mechanisms of antitumor immunity, 
the current knowledge allows the development of strate-
gies to boost antitumor immune responses in different 
ways as we will discuss in this review. 
 
IMMUNE SYSTEM ACTIVATION BY IMMUNOGENIC 
CELL DEATH (ICD) 
Deregulated cell death is a common feature of many hu-
man diseases and it is associated with hyper-proliferative 
disorders, such as cancer [14]. One of the underlying 
mechanisms proposed by Hanahan and colleagues is the 
unresponsiveness of tumor cells to the control pathways 
that regulate proliferation and cell death [15]. Cell death 
can be classified according to its morphological appearance, 
enzymatic criteria, functional aspects or immunological 
characteristics. Several types of cell deaths have been re-
ported but there is an increase interest in understanding 
which are the cancer cells that are susceptible to death, 
where, how, and which immune cells are able to “recog-
nize” them and present their tumor-associated antigens to 
ultimately activate the immune response [16].  
Two major barriers usually avoid the malignant trans-
formation of cells in the human body. First, the activation 
of oncogenes often stimulates a DNA damage response 
that finally culminates in apoptosis and hence elimination 
of the mutated cells. Second, the immune system recog-
nizes transformed cells, based on the tumor-specific ex-
pression of abnormal or mutated antigens and damage 
associated molecular patterns (DAMPs) which can trigger 
the immune response [17]. Little more than a decade ago it 
was shown that chemotherapy induces a type of cell death, 
called immunogenic cell death (ICD) that, at least in some 
cases, activates effector mechanisms directed against dy-
ing tumor cells, required for an optimal therapeutic effect 
[18]. 
The concept of ICD capable of converting tumors into 
an in situ vaccine was proposed as an efficient way to in-
duce the activation of endogenous immune responses. This 
type of cell death is characterized by the induction of dif-
ferent DAMPs mediated by endoplasmic reticulum (ER) 
stress and autophagy, which stimulates cross presentation 
of tumor cell-derived antigens by dendritic cells (DCs) [19]. 
ICD is in fact a multifactorial process that involves changes 
in the composition of the cell membrane and the secretion 
of soluble factors in a well-defined timeline. 
First, the translocation of calreticulin (CRT) from the 
perinuclear ER to the cancer cell membrane concomitantly 
with the re-localization of ERp57 will work as an “eat me” 
signal to induce phagocytosis by DCs, along with the induc-
tion of antigen presentation to activate antigen-specific T 
cells [20]. During the blebbing phase of cell death, autoph-
agy-dependent ATP secretion will enter the equation to 
play the role of the “find me” signal. During the autophagy 
process the complex autophagolysosome will fuse with the 
plasma membrane allowing the release of the “find me” 
signal [21]. ATP will act as chemoattractant and activate 
the purinergic receptor P2X7 on DCs triggering NALP3-ASC 
(nacht domain-, leucine-rich repeat-, and pyrin domain 
containing protein 3; speck-like protein) inflammasome 
activation and the production of IL-1β [22]. This pathway 
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will provide cytokines that are necessary in the context of 
antigen presentation [23]. Moreover, during the late stages 
of apoptosis, High-mobility group box 1 protein (HMGB1) 
can be released from the nucleus to the cytoplasm and 
finally to the extracellular environment to bind to the Toll 
Like Receptor 4 (TLR4) expressed on DCs to induce their 
activation. This binding will trigger MyD88 signaling to en-
hance antigen processing and antigen presentation by in-
hibiting the fusion of the phagosomes and lysosomes facili-
tating the cargo of antigens for presentation [24, 25]. The 
expression of ecto-HSP70 and -HSP90 on the tumor cell 
membrane also contributes to the tumor clearance 
through the induction of a tumor-specific CD8 T cell re-
sponse [26]. 
 
Classical ICD inducers 
The traditional view of anticancer therapy as an immuno-
suppressive or tolerogenic regimen has been challenged by 
several lines of evidence indicating that some cytotoxic 
drugs trigger an effective immune response by inducing 
apoptotic tumor cell death [27]. Today, it is well known 
that in response to many chemotherapeutic and cell dam-
aging agents like etoposide, mitomycin C, thapsigargin or 
cisplatin, tumor cells die in a non-immunogenic fashion. 
However, cancer cells treated with anthracyclines such as 
doxorubicin, mitoxantrone, oxaliplatin or ionizing irradia-
tion can induce a strong antitumor immune response. 
Kroemer and collaborators showed in a series of experi-
ments that anthracycline-treated cells injected subcutane-
ously in immunocompetent mice, in the absence of any 
adjuvant, are able to induce immune system activation, 
acting as an “in situ vaccine” [26, 27, 28].  
To date, several screening studies have been carried 
out to discover bona fide ICD inducers and revealed the 
inherent capacity of a wide variety of drugs to induce cell 
death-associated exposure of danger signals and to drive in 
vivo anticancer immune responses [28]. Two kinds of ICD 
inducers have been described, type I and type II. Anthracy-
clines and analogues are classified as ICD inducers type I, 
while the photodynamic therapy (PDT) or the oncolytic 
viruses are type II, as summarized in Table 1. PDT uses non-
toxic photosensitizers and visible light at a specific wave-
length in combination with oxygen to produce reactive 
oxygen species (ROS) that kill malignant cells. As a type II 
ICD inducer, it differs from type I in the CRT exposure 
pathway. After PDT, ATP release depends on ER stress and 
CRT exposure depends on ROS formation, but not on eIF2α 
(the eukaryotic initiation factor 2 α) phosphorylation, 
caspase-8 activation or ERp57 translocation which are the 
key features of type I ICD inducers [23]. 
Moreover, recent evidence places ER stress at the core 
of all the scenarios where ICD occurs, irrespective of the 
types. ER stress and unfolded protein response (UPR) are 
required for the CRT exposure on the cell surface during 
ICD and consist in the simultaneous activation of three 
pathways: i) the PERK (eukaryotic translation initiation 
factor 2 alpha kinase 3)-mediated phosphorylation of eIF2α, 
that induces the expression of ATF4 (activating transcrip-
tion factor 4), ii) the translocation of ATF6 (activating tran-
scription factor 6) from the ER to the Golgi and then to the 
nucleus, and iii) the IRE1α (endoplasmic reticulin to nucle-
us signaling 1)-mediated splicing of XBP1 (X-box binding 
protein 1). These three transcription factors activate a 
gene expression profile to facilitate apoptosis [29]. Thus, 
Table 1. Classical ICD inducers. 
 Inducer Cell line Signals Action 




ROS, DAMPs, ATP, ER 
Stress  
 




BBL-5, B16  
 
CRT, HMGB1  
 




CT26, B16F10, gp100 
Mell, DU145, OV90, 
AML cells  
CRT, HMGB1, ATP, 
HSP 
 
ICD with autophagy, increase phagocy-
tosis, DC activation, antitumor specific 
response [20, 26, 27] 
Oxaliplatin 
 
CT26, RKO, HCT116 CRT, HMGB1, 
caspase- 8  
 
ICD induced, positive correlation with 
efficacy in colon cancer patients [108] 
Ionizing radiation CT26, MCA205 CRT, HSP70 Partially dependent antitumor T cell 
response [109, 110] 
Cardiac glycosides U2OS CRT, ATP, HMB1, 
HSP90 
ICD induction, increase survival in 
breast, colorectal, head and neck and 
hepatocellular carcinomas [111]  
Type II Oncolytic Virus GL261 glioma cells  
 
ER Stress, HMGB1, 
ATP, CRT  
NK cell activation, macrophage and 




LLC, EMT6, C127, U87 
 
ROS, Autophagy, 
HMGB1, HSPs, CRT 
DC activation, adaptive immunity-
dependent antitumor response [23] 
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ER stress and the UPR have emerged as important targets 
in different human cancers, for example in multiple mye-
loma. In this hematological malignancy of mature antibody 
secreting plasma cells, the constant and elevated produc-
tion of immunoglobulins leaves these cells heavily reliant 
on the activation of the UPR [30]. For this reason, drugs 
that disrupt ER homeostasis and engage ER stress-
associated cell death, such as proteasome inhibitors as well 
as novel ER stressors, are intended to be promising thera-
peutic agents in this setting [30].  
During tumor development, cancer cells have to cope 
with harsh conditions that trigger ER stress. Thus, UPR acti-
vation constitutes an important hallmark of several human 
cancers since it endows cancer cells with the ability to ac-
quire essential characteristics required for tumor progres-
sion [31]. In transformed cells the need for protein and 
lipid production is increased for rapid proliferation for the 
adaptation to a particular oxygen and nutrient deprived 
environment. To overcome such challenges cancer cells, 
exploit intrinsic mechanisms such as UPR for survival. UPR 
signaling supports tumor development in several ways: i) 
by promoting cell cycle progression and cell proliferation 
pathways, ii) by promoting the expression of pro-
angiogenic factors in response to hypoxia, iii) by inducing 
the recruitment of several types of cells into the tumor 
microenvironment to evade the immune response and iiii) 
by favoring the epithelial to mesenchymal transition by 
overcoming the stress of cell detachment [32].     
 
Natural products as non-classical ICD inducers 
Two categories of natural products can be distinguished 
and considered as immune system activators: single com-
pounds derived from natural sources or natural complex 
fractions composed of a large number of molecules. A non-
exhaustive overview of these products is presented in Ta-
ble 2.  
 
Single molecules 
Shikonin (SK), a secondary plant metabolite isolated from 
Lithospermum erythrorhizon, has been described as having 
several biological activities that include the inhibition of 
the promoters of pro-inflammatory cytokines such as TNF-
α [33] and GM-CSF [34] and the splicing of TNF-α pre-
mRNA [35]. Moreover, for SK and its derivatives anti-
tumoral properties through ICD induction have been de-
scribed [36]. In fact, SK has been shown to induce the ex-
pression of different DAMPs including CRT, HMGB1, 
GRPp78, HSP70 and HSP90 in several tumor cell lines. 
Moreover, tumor cells treated with SK and lipopolysaccha-
ride (LPS) activate DCs and induce the differentiation of 
tumor-specific Th1 and Th17 CD4 T cells [36]. Further stud-
ies showed that the heterogeneous nuclear ribonucleopro-
tein A1 (hnRNPA1) is also a specific protein target of SK and 
that its suppression is necessary for the expression of the 
signals that play a major role in ICD induction. All together 
these reports demonstrate the multi-target capacity of SK 
[37]. A second example of an isolated compound is Hyperi-
cin, an anthraquinone derivative which in combination 
with Hyperforin is one of the principal components of the 
Hypericum flower plant, commonly named Saint John’s 
wort. Recently, the use of DC vaccines in combination with 
hypericin-based PDT (Hyp-PDT) was shown to induce ICD 
and was tested to treat Hight Grade Gliomas (HGG) in an 
animal model. It could be shown that the DC vaccine:Hyp-
PDT combination improved survival of tumor-bearing ani-
mals, and that the effect was dependent on cell-associated 
ROS production and the release of DAMPs [38], including 
extra-cellular HMGB1 and cell surface CRT [39]. These find-
ings suggest that Hyp-PDT–based anticancer vaccines are 
worth additional assessments for clinical use in the future. 
 
Complex fractions 
Complex fractions can have immunomodulatory capacities 
and antitumor activity as indicated recently by Turrini et al., 
who showed that a decoction from plant roots of Hemi-
desmus indicus is able to induce ER stress along with the 
hallmarks of ICD to stimulate DC maturation and the up-
regulation of CD83 as a costimulatory signal [40]. Moreo-
ver, P2Et, a gallotannin-rich fraction extracted from the red 
fruits of Caesalpinia spinosa, was initially reported for its 
TABLE 2. Natural products reported as ICD inducers. 












B16 DAPMs, tumor antigens ICD induced, DC activation, 
Th1/Th17 specific response [37] 
Wogonine (Scutellaria 
baicalensis) 
MFC CRT, ATP, HMGB1, ROS, ER 
stress 
ICD induction, increase lympho-








CRT, ATP, HMGB1, autoph-
agy, ROS, caspase 8, mito-
chondrial membrane depo-
larization 
ICD induction, multifunctional T 
cell response and chemotherapy 
adjuvant (4T1). Specific T CD8 
response (B16). [42, 43, 102] 
Hemidesmus indicus 
decoction 
DLD ER stress, ATP, HMGB1, 
CD83 
DC maturation after ICD induc-
tion [40] 
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cytotoxic properties on several cancer cell lines [41]. P2Et 
has been previously characterized as a complex polyphe-
nol-rich fraction with antitumoral activity and was shown 
to contain a large amount of gallic acid after acid hydrolysis, 
mainly due to the presence of gallic acid derivatives like 
galloyl quinic acids. Chromatographic fingerprint using 
HPLC/PDA revealed that most compounds in the fraction 
absorb at a wavelength of 254 nm, which is characteristic 
for some polyphenolic compounds and gallotannins [42]. 
More recently, complementary studies have shown that 
P2Et induces immunogenic apoptosis through the expres-
sion of extracellular CRT, HMGB1, ATP and autophagy in 
preclinical models of breast carcinoma [42] and metastatic 
melanoma [43]. Furthermore, P2Et not only induces the 
expression of the cellular markers of ICD but also activates 
an immune-dependent antitumor activity. As for SK, P2Et 
treated cancer cells act as a therapeutic vaccine that delays 
tumor growth in the B16-F10 melanoma model, through 
the induction of functional antigen-specific CD8 T cells [43]. 
In addition, it was also recently shown that the ICD induced 
by P2Et is due to ER stress and PERK-dependent calcium 
release [44]. 
 
NATURAL PRODUCTS AS ICD-INDEPENDENT ACTIVA-
TORS OF THE IMMUNE SYSTEM 
Plant- or animal-derived natural products have different 
biological properties that can induce or sustain immune 
responses while also targeting tumor cells through ICD-
independent mechanisms. For example, natural single 
molecule derivates such as phyllanthusmin C, curcumin, 
chitosan and methyl gallate derivatives possess immuno-
regulatory properties influencing the innate and/or adap-
tive antitumor immunity. The Ellagic acid peracetate deri-
vate from methyl gallate found in wine (among other 
sources), is able to significantly reduce tumor growth in the 
B16-F10 melanoma mouse model by increasing the num-
ber of immune cells, while inducing tumor cell death via 
the decrease of the anti-apoptotic BCL-2 protein [45]. Fur-
ther, chitosan present in high quantities in shrimp shells 
has been reported as a non-toxic natural compound with 
cytotoxic capacity against the sarcoma 180 (S180) tumor 
cell line and as an innate immune system activator [46]. 
The treatment with chitosan in leukemia and B16-F10 
models showed direct activity on DCs by inducing IL-12 and 
IL-15 secretion followed by STAT4 and NFkB activation in 
natural killer (NK) cells to increase their survival, cytotoxici-
ty and IFN-γ production [46]. Conversely, Phyllanthusmin C 
isolated from Phyllanthus reticulatus acts directly on NK 
cells by promoting NFκB signaling enhancement and finally 
inducing IFN-γ secretion regardless of the DC activation or 
the presence of IL-12 or IL-15 in the media [47]. 
The activation of the adaptive immune system can be 
induced by both single compounds, as curcumin, and natu-
ral complex fractions, as herbal medicine juzen-taiho-to 
(JTT). On one side, Curcumin derived from Curcuma longa 
has been reported as having antitumor activity through the 
induction of apoptosis in tumor cells [48] but also, and very 
importantly, by attenuating the immunosuppressive tumor 
microenvironment in vivo. In 2012 Chang et al. demon-
strated that the in vivo treatment with curcumin in combi-
nation with T cell transfer increases tumor infiltration and 
restores the antitumor activity of transferred CD8 T cells by 
inhibiting IDO and TGFβ production by tumor cells [49]. On 
the other side, a complex mixture composed of ten differ-
ent herbs called JTT, which is widely used in clinics in Japan, 
has been shown to activate the adaptive immune response 
in vivo in tumor models. Using the RET-transgenic mela-
noma mouse model, in 2001 Dai et al. showed that oral 
administration of JTT significantly delayed tumor growth 
and improved survival. They proposed a model where JTT 
does not act directly on the tumor cells but rather through 
T cell cytotoxicity [50]. 
 
EFFICACY LOSS BY REDUCING THE COMPONENTS OF 
COMPLEX FRACTIONS 
Guided fractionation is commonly used to study complex 
botanical preparations and determine their biologically 
active compounds. Petiveria alliacea Linn (P. alliacea) is 
commonly used in traditional medicine in Central and 
South America and the Caribbean cost. Infusions made 
with the leaves and stems of this plant have been used to 
treat leukemia and breast cancer by the native communi-
ties [51]. However, the mechanism of action in cancer has 
been only partially described. The work of Hernandez et al. 
showed that the plant extract obtained from the leaves of 
P. alliacea induces breast cancer cell death through the 
modulation of their glycolytic metabolism 52, 53]. This 
extract was characterized by HPLC and the principal com-
ponents were identified. Several subfractions from the 
original one (guided fractionation) were evaluated for their 
antitumor activity and the IC50 revealed lower biological 
activity compared to the original fraction. These findings 
support the importance of the complex interaction among 
components (Susana Fiorentino, personal communication).  
Another significant indication of this phenomenon is il-
lustrated by the work by Junio et al. were they evaluated 
the properties and the components of a botanical medicine 
made from Hydrastis canadensis (Goldenseal) [54]. This 
preparation is ranked among the 20 most commonly used 
herbal preparations worldwide and is recommended to 
treat viral and bacterial infections and diarrhea. Goldenseal 
extracts from leaves and roots are rich in alkaloids like ber-
berine that is reported to have antimicrobial activity. How-
ever, previous work by the same group showed that ber-
berine alone has only little biological activity and that in 
the mixture, other compounds might play a role [55]. Fur-
ther investigations showed that the extract was also rich in 
flavonoids which could block multidrug resistance efflux 
pumps and thereby increase efficacy in the absence of 
antibacterial properties. Their work described the directed 
fractionation of the original preparation to characterize the 
components, demonstrating that single compounds do not 
fully account for the biological activity of the main prepara-
tions 55].   
As illustrated in this section, natural products represent 
a versatile “chemical toolbox” of potent medicines with 
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verified health promoting active principles (Table 2 and 
Table 3). However, a consistent issue in research on natu-
ral products is the lack of clarity surrounding their mecha-
nism(s) of actions and/or their exact composition [56]. 
Since each natural product is capable of binding to multiple 
proteins with unrelated structures, each small molecule 
may have multiple targets. In that respect, an interesting 
question remains: can we profit from this multi-target 
property or should we avoid it? 
 
MULTI-TARGET PHYTOTHERAPY IN CANCER: PROS AND 
CONS  
As mentioned above, one of the main characteristics of 
botanical extracts relies on their complexity, rendering the 
identification of all molecular targets within the extracts 
difficult to be determined. But how do these complex 
preparations work? It might be speculated that they are 
able to modify different proteins to a certain extent within 
the same network, but it is also possible that weak effects 
induced by the whole are sufficient to have a pharmacolog-
ical effect without having identified a major compound. 
Almost 20 years ago few pioneering groups reported the 
possible benefit of the multitarget profile of biological ac-
tive small molecules [57, 58]. Since then, the field of 
polypharmacology and multi-target drug discovery have 
been growing, and have proposed new concepts to over-
come the major limitations of classical “one target, one 
drug” strategies [59]. Instead of single target agents, the 
identification of molecules or combinations that have mul-
tiple interconnected targets or act on similar networks 
might be beneficial.  
Herbal formulations are mainly composed of multiple 
biologically active molecules and several studies have 
proven their benefits in different types of diseases. How-
ever, they are not fully accepted as standard treatments 
mainly due to their complex nature and the lack of strin-
gent quality control in their preparation [60].   
The primary aim of traditional phytotherapy is to use 
plant extracts to create complex combinations, where even 
the “single” extracts are mixtures of different molecules. 
As a result, in China, formulations of complex botanical 
products have been evolving overtime, with more than 
100,000 currently being documented. Instead, western 
pharmacologists are mostly confused by their complexity, 
although several combination therapies are commonly 
used for the treatment of pain [61], AIDS [62, 63] or cancer 
to prevent chemoresistance [64], highlighting the ad-
vantages of multi-target approaches.     
One of the best examples to better illustrate the poten-
tial multi-target activity of natural products comes from 
the analysis of the multiple bioactivities of green tea prep-
arations. To date, a significant number of studies has 
demonstrated that green tea has health beneficial effects 
which include reduction of serum cholesterol, prevention 
of low-density lipoprotein oxidation and decreased risk of 
cardiovascular disorders and cancer [65]. Many of these 
effects are most likely mediated by polyphenols contained 
in green tea, such as flavonoids and flavonols. One of the 
most studied flavonols is the epigallocatechin-3-gallate 
(EGCG) that has been reported for its anticancer activity 
and the potential to interfere with multiple signaling path-
ways in cancer cells [66]: i) by binding to the BH3 pocket of 
Bcl-2 family proteins to inhibit their antiapoptotic function 
[67]; ii) by inhibiting the NFκB activity and MAPK pathway 
in human colon cancer cells [66]; iii) by the specific inhibi-
tion of the chymotrypsin-like activity in the proteasome in 
vitro and in vivo [68]; iv) by the inhibition of the matrix 
metalloproteinases (MMP) 2 and 9 in the prostate of 
TRAMP mice [69]. 
As for the P2Et example, this fraction includes in its 
composition gallotannins-like ethyl gallate and gallic acid in 
high proportion. The comparison of the effect of the full 
fraction to the isolated compounds showed that the single 
molecules have very different effects on autophagy, being 
individually less effective in inducing the DAMPs required 
for ICD in the cancer therapy context. To obtain results 
comparable to the whole extract, almost 20 times more of 
the single molecules is required, which in turn might result 
in increased toxicity (Alfonso Barreto, personal communi-
cation). Hence, attempts to reproduce the effects of com-
TABLE 3. Other immune system activating natural products. 
 Inducer Model Signals Action 
Single mole-
cules 
Phyllanthusmin C  
 
Human primary NK 
cells 
IFNγ NK activation [47] 
Curcumin E.G7 Reduction of IDO 
and TGFβ 
Increase of CD8 T cell antitumor ef-
fector functions [49] 
Chitosan Sarcoma 180, 
B16F10 
IL-12, IL-15, IFNγ DC and NK activation [46] 
Methyl Gallate 
derivates 
B16F10 Reduction of BCL2 
proteins 
Apoptosis induction and increased 
immune cell numbers [45] 
Complex 
formulations 
Juzen-taiho-to Mel-Ret  T cell activation and enhanced cyto-
toxic activity [50] 
Astragalus mem-
branaceus 
Spleen cells TNF, IL-6 Spleen cell proliferation, B cell re-
sponse, Alloantigen specific CTL re-
sponse, Macrophage activation [114] 
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plex formulations by single molecules may prove unsuc-
cessful.   
However, as in the case of drug combinations, molecu-
lar interactions in complex plant formulations might be 
antagonistic or dangerous since botanical preparations can 
contain toxic or even lethal compounds. Some compounds 
such as Pyrrolizidine alkaloids, secondary metabolites, 
need to be removed due to their hepatotoxicity [70] or 
aristolochic acid is known to promote kidney nephropathy 
[71]. Moreover, the increased use of herbs for self-
medication is resulting in opposite outcomes depending on 
the context [72], as recently reported for the P2Et fraction. 
As mentioned above, this fraction was initially described to 
induce ICD and immune system activation in preclinical 
tumor mouse models [42, 43] but additional studies 
showed pro-tumoral effects if used in a prophylactic con-
text [73]. These examples reinforce the need to be proac-
tive to develop appropriate measures to test the safety, 
the quality and the mechanisms of action of public accessi-
ble natural products. 
 
NETWORK PHARMACOLOGY: MULTI-TARGETING AND 
MULTI-DISEASE CONCEPT 
To fight complex diseases such as cancer, cardiovascular 
diseases, AIDS or neurodegenerative disorders, the ap-
proach of single target drugs has shown discouraging re-
sults [74]. In contrast, multiple target drugs or combina-
tions are more efficient and, in many cases, shows less 
toxicity [75]. The concept of signaling network analysis, or 
network pharmacology (NP), proposed initially by Hopkins 
in 2008, appears as a suitable tool to assess complex inter-
actions and find new targets for “rational drug discovery”, 
by evaluating drug mechanisms of action through a biolog-
ical network and its comparison with the target model [76]. 
Today, drug discovery could benefit from network-based 
approaches to overcome problems such as the lack of effi-
cacy, the potential resistance to compounds with a single 
target and toxic interactions among different components 
[76, 77]. This new concept intends to improve the predic-
tion of drug targets in public databases and promote the 
use of network models using high-throughput screening 
and bioinformatics.  
NP analysis of traditional medicines is becoming a pop-
ular approach to identify treatments of complex and multi-
factorial diseases, as reported in several studies that ap-
plied NP to assess natural complex fractions composed of 
different ingredients, unknown targets and different 
pharmacological mechanisms [78-80].   
While drug actions have been originally considered as a 
“lock and key system [81], a growing evidence is revealing 
a more complex picture. Yildirim et al. in 2007 described 
that there are many keys for one lock and that this phe-
nomenon is quite common as proteins rarely function as 
isolated entities, whereas they rather act as part of a highly 
interconnected cellular network [82]. Re-thinking drug 
action in the context of network biology may provide in-
sights into how we can improve drug discovery for complex 
diseases. Further, NP analysis predicts that modulating 
multiple proteins might be required to fight against com-
plex and strong phenotypes in a more effective way that 
only deleting individual nodes, having only little effect on 
the whole disease network [2]. For example, the combina-
torial therapies used against hepatitis C virus (HCV) were 
conceived on the hypothesis that targeting two different 
nodes of HCV replication may exhibit superior antiviral 
activity and reduce resistance compared to single drugs 
[81]; the recent increase of multi-target drugs to treat 
schizophrenia and major depressive disorders aims at tar-
geting the complexity and multifactorial nature of such 
disorders [81, 83].  
In the case of Traditional Chinese Medicines (TCM) the 
molecular mechanisms of action for many formulations 
remain unclear. To solve this problem a TCMAnalyzer was 
recently developed. This tool designed by Liu et al. can be 
used to identify the potential compounds responsible for 
the biological activity, to investigate the molecular mecha-
nisms at a systematic level and to explore the potential 
targeted bioactive herbs [84].  
The molecular network analysis of the TCM is not re-
stricted to the identification of the mechanism of action; it 
has also been important to explain and study the compati-
bility or possible toxic interactions among the different 
compounds of complex preparations [77, 85]. In 2010 Li et 
al. proposed a method named the Distance-based Mutual 
Information Model (DMIM) to identify useful relationships 
among the herbal components of several complex formu-
las. DMIM combines mutual information entropy and “dis-
tances” between the different herbs to construct an herb 
network that allows to illustrate the traditional herbal pair-
ing and compatibility [86]. Equally important, the concept 
of network toxicology uses the principles of NP for the un-
derstanding of the “toxic-gene-target-drug” interaction 
network to predict and estimate the toxicity and side ef-
fects of drugs or complex formulations [85]. Technologies 
that feature high-throughput screening, toxic compounds 
exclusion and drug-target network might be very im-
portant for active ingredient screening and toxicity as-
sessment [85]. In the work of Fan et al., NP was used to 
reconstruct the network of “compound-protein/gene-
toxicity” to identify the toxic molecules and predict the 
side effects of the known compounds. This helps to im-
prove the safety of natural complex preparations and to 
understand toxic mechanisms. Currently several databases 
for the study of network toxicology include CTD [87], TOX-
NET [88] and the National Toxicology Program [85], among 
others. 
 
Network pharmacology in cancer 
Cancer is a multifactorial disease [89]. For this reason, the 
seek for multi-target drugs represents a promising ap-
proach to understand how signaling networks are altered 
in transformed cells and to identify pertinent targets dur-
ing drug discovery [90]. For example, the NP approach was 
instrumental to identify altered autophagy-associated 
genes and to reveal which alterations in this pathway cor-
related with patient survival. Overall, this strategy might 
contribute to identifying the specific signaling pathways 
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that drive pro- or antitumor signals [76]. For that purpose, 
Wong et al. used a computer-aided drug design (CADD) 
method applied simultaneously to multiple drug targets 
and systems biology [91]. They evaluated the core network 
markers of four cancer types (colon, liver, lung and blad-
der) by systems biology followed by computational analysis 
and identified 28 cancer housekeeping proteins. Using this 
information, wet-bench researchers combined the top 
ligands for each of the 28 core proteins and found that 
they could decrease the IC50 with concomitant increase in 
cell death using a multidrug approach with different tar-
gets [91]. Further, in the ICD context where ER stress in-
duction with PERK activation are indispensable steps to 
initiate the immunogenic apoptotic axis [92] NP would 
allow to dissect the biological networks targeted by differ-
ent therapeutic options (e.g. single molecules, complex 
formulations or combinatorial therapies). This would ena-
ble us to predict specific candidates capable of triggering 
ROS production, Ca2+ alterations or defaults in glucose con-
sumption and contribute to propose bona fide ICD inducers 
with the characteristics mentioned in Table 1. 
Another attractive possibility would imply the use of 
the network analysis to identify and prioritize several hubs 
associated with the response to immunotherapy, such as 
immune checkpoint blockade. In the previously cited work 
of Lesterhuis et al., they identified context dependent gene 
expressions that were only visible after NP analysis. They 
also applied a drug repurposing approach to the response-
associated network data and identified pleiotropic drugs 
that improved the response rate to anti-CTLA4 and that 
had never been associated with antitumor properties and 
could have never been predicted to work [93].  
The complex tumor microenvironment and the im-
munomodulation that characterize it are often difficult to 
be addressed at the same time with a single therapeutic 
agent and several approaches remain unsuccessful or in-
sufficient. For instance, autophagy’s role and regulation 
during cancer development has been the topic of long de-
bates due to the opposite effects reported in the literature. 
In line with this, the use of metformin to induce autophagy 
as effective cancer treatment has encountered difficulties 
during clinical trials [94]. Further, ER stress and UPR are 
involved in several types of cancer and they are frequently 
correlated with advanced stage and chemoresistance. UPR 
is important for changes in gene expression that can con-
tribute either to prevention or survival during tumor de-
velopment and can be modulated by chemotherapy but 
the clinical implications are only beginning to be under-
stood [95]. Lastly, tumor infiltrating T cell impairment and 
hijacking of immune system effectors remain one of the 
most complex problems for immunotherapeutic approach-
es [96] despite the FDA approval of several immune check-
point inhibitors [97].  
In a similar way, natural products and NP approaches 
are being used to discover new agents or indicate new 
combinations to improve current therapies [98, 99]. Multi-
target natural dietary supplements containing some ingre-
dients such as Ginseng extracts, Grape seed extracts, and 
curcumin have been shown to promote recovery from se-
vere illnesses, and relieve standard therapy-induced side 
effects [100]. Interestingly, clinical trials have also proven 
that some natural products can reduce chemotherapy and 
radiotherapy-induced toxicity [101]. Common gastrointes-
tinal toxicity side effects of chemotherapy can be reduced 
by natural products. Red Ginseng decreases nausea, vomit-
ing, dyspnea and fatigue after taxan and platinum-based 
chemotherapy [101].  
Natural fractions not only help to counteract drug side 
effects. Their activity can also exert synergistic effects with 
conventional treatments and antitumor activity by over-
coming drug resistance. In 2016 Sandoval et al., showed 
that the P2Et fraction exerts synergistic activity with doxo-
rubicin in vitro in several cancer lines and in vivo in a 
mouse model transplanted with a doxorubicin-resistant 
breast cancer cell line (TSA). Interestingly, P2Et extract 
revealed a synergistic effect with doxorubicin in resistant 
cell lines, and its effect does not seem to be mediated by 
ROS increase [102]. 
Another example is the combination of PHY906, a Chi-
nese traditional complex formulation consisting of four 
different herbs, with Irinotecan (CPT-11) as treatment for 
metastatic colon or rectal carcinoma [103]. In 2010, Lam et 
al. used the MC38 mouse model to show that PHY906 in-
creased the antitumor activity of CPT-11, while decreasing 
poor prognostic factors as weight loss and promoting intes-
tinal recovery from the chemotherapy damage. PHY906 
was promoting the expression of intestinal progenitor or 
stem cell markers through the Wnt/β-catenin pathway and 
at the same time inhibiting inflammation [60]. These re-
sults suggest that the development of complex, multi-
component herbal medicines that are able to target multi-
ple sites and activating different signaling pathways could 
be useful for future drug development and as an add-on 
for improving current standard treatments. 
 
CONCLUSIONS 
Historically, natural products have been the source of a 
great variety of medicinal preparations and today they 
continue to provide prototypes for pharmacologically ac-
tive compounds, particularly as anticancer and antimicro-
bial agents. According to the World Health Organization 
(WHO), 80% of people still rely on traditional plant-based 
medicines for primary health care and the plant-derived 
drugs remain related to their original ethno pharmacologi-
cal usage. In addition, in this review we intended to stress 
the capacity of natural products to influence the immune 
system by either affecting the functions of immune cells or 
by directly acting on malignant transformed cells to turn 
them into intrinsic immune cell activators, showing the 
potential of natural products as immunomodulators. The 
results discussed here put in evidence the importance of 
dissecting the molecular mechanisms of the immunomodu-
latory effects of the natural compounds since this could 
lead to the discovery of novel and promising candidates 
that can be used in future immunotherapeutic strategies.  
However, the complex composition and the multitarget 
capacities of natural products remains one of the main 
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concerns for the western medicine due to safety and quali-
ty control reasons. Nevertheless, NP approaches as the 
ones mentioned here could help to put in place standardi-
zation protocols of proved bioactive compounds or formu-
lations to elucidate the molecular mechanisms of action 
and therefore facilitate their inclusion in clinical trials and 
their commercialization.  
In order to promote and improve the quality of herbal 
medicines and to reduce the proportion of adverse events 
attributable to their poor quality, the WHO has also com-
mitted to the development of a series of technical guide-
lines related to quality assurance and control of herbal 
medicines [104]. Finally, the European framework has pro-
vided a powerful regulation model for the harmonization 
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